---
category: disclosure
circular_id: fba623e12ff27fa4
date: '2025-08-01'
description: Lupin Limited and Sun Pharmaceutical Industries clarify they did not
  receive letters from US government regarding drug pricing as reported in media.
draft: false
guid: https://www.bseindia.com/markets/MarketInfo/DispNoticesNCirculars.aspx?Noticeid={7F013B62-C7E0-4E4E-8140-D6DE5D984C34}&noticeno=20250801-65&dt=08/01/2025&icount=65&totcount=80&flag=0
impact: medium
impact_ranking: medium
importance_ranking: medium
justification: Market clarification from major pharma companies addressing media reports
  affecting stock prices
pdf_url: https://www.bseindia.com/markets/MarketInfo/DownloadAttach.aspx?id=20250801-65&attachedId=a85e14af-98d9-48af-a5af-bef625026bf5
processing:
  attempts: 1
  content_hash: ed18f6a9c933a73b
  processed_at: '2025-08-01T18:36:20.542342'
  processor_version: '2.0'
  stage: completed
  status: published
published_date: '2025-08-01T13:53:53+00:00'
rss_url: https://www.bseindia.com/markets/MarketInfo/DispNoticesNCirculars.aspx?Noticeid={7F013B62-C7E0-4E4E-8140-D6DE5D984C34}&noticeno=20250801-65&dt=08/01/2025&icount=65&totcount=80&flag=0
severity: medium
source: bse
stocks:
- LUPIN
- SUNPHARMA
tags:
- media-clarification
- pharma-sector
- us-drug-pricing
- stock-price-movement
- regulatory-disclosure
title: BSE Clarifications from Companies - Lupin and Sun Pharma Respond to Trump Drug
  Pricing Letter Reports
---

## Summary

Lupin Limited and Sun Pharmaceutical Industries Limited have issued clarifications to BSE and NSE regarding media reports claiming that US President Trump sent letters to 17 global pharmaceutical companies seeking lower drug prices. Both companies confirmed they did not receive any such letters from the US government and stated there is no material impact on their operations.

## Key Points

- Both Lupin and Sun Pharma confirmed they did not receive letters from the US government regarding drug pricing
- The clarifications were issued in response to stock exchange queries about news reports on www.moneycontrol.com
- Companies stated there is no company-specific development or material impact
- Both companies emphasized compliance with SEBI disclosure regulations
- Stock price movements were attributed to general market reaction to the news report

## Regulatory Changes

No regulatory changes announced in this circular.

## Compliance Requirements

- Companies required to clarify media reports that could impact stock prices
- Continued compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015
- Prompt disclosure of material events as and when they occur

## Important Dates

- August 01, 2025: Date of clarification letters from both companies
- July 31, 2025: Reported date when US President allegedly sent letters (as per media reports)

## Impact Assessment

The clarifications aim to address market concerns and provide transparency regarding the companies' involvement in reported US drug pricing initiatives. Both companies emphasized that the media reports were not specific to them and no material impact is expected on their operations. The responses demonstrate proactive disclosure practices to maintain market confidence.